In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016) | Zendy

Michael A. Pfaller | Zendy; Rodrigo E. Mendes | Zendy; Leonard R Duncan | Zendy; Robert K. Flamm | Zendy; Hélio S. Sader | Zendy

Open Access

In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)

Author(s) -

Michael A. Pfaller,

Rodrigo E. Mendes,

Leonard R Duncan,

Robert K. Flamm,

Hélio S. Sader

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01555-17

Subject(s) - tigecycline , streptococcus pneumoniae , broth microdilution , levofloxacin , linezolid , microbiology and biotechnology , medicine , antimicrobial , cephalosporin , antibiotics , biology , minimum inhibitory concentration , staphylococcus aureus , bacteria , vancomycin , genetics

We evaluated trends inStreptococcus pneumoniae antimicrobial susceptibility in United States hospitals in the 2010 to 2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7% and 12.4%, respectively, in 2010 to 17.7% and 3.6%, respectively, in 2016. The susceptibilities to most comparator antimicrobial agents increased, whereas the susceptibilities to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity againstS. pneumoniae (>99.9%) with no marked variations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research